Abstract
The extremely low reporting rate of cardiovascular adverse events for loratadine, the possible preferential use of loratadine in patients with pre-existing cardiovascular disorders, and the impressive lack of cardiovascular effects at extremely high concentrations in clinical and preclinical studies demonstrate the very safe cardiovascular profile of loratadine.
MeSH terms
-
Animals
-
Cardiovascular System / drug effects*
-
Cation Transport Proteins*
-
DNA-Binding Proteins*
-
Drug Interactions
-
ERG1 Potassium Channel
-
Electrocardiography / drug effects
-
Ether-A-Go-Go Potassium Channels
-
Histamine H1 Antagonists / adverse effects*
-
Humans
-
Loratadine / adverse effects*
-
Potassium Channels / drug effects
-
Potassium Channels, Voltage-Gated*
-
Trans-Activators*
-
Transcriptional Regulator ERG
Substances
-
Cation Transport Proteins
-
DNA-Binding Proteins
-
ERG protein, human
-
ERG1 Potassium Channel
-
Ether-A-Go-Go Potassium Channels
-
Histamine H1 Antagonists
-
KCNH6 protein, human
-
Potassium Channels
-
Potassium Channels, Voltage-Gated
-
Trans-Activators
-
Transcriptional Regulator ERG
-
Loratadine